MedTrace Logo

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

NCT05595590 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-10-27

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of pulsed radiotherapy given concomitantly with Tislelizumab and as maintenance therapy in participants with locoregionally recurrent head and neck squamous cell carcinoma ( HNSCC).

Conditions

Interventions

DRUG

Tislelizumab

Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W)

RADIATION

Pulse radiation

66-70Gy/33-35Fx, 2Gy/Fx.

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Ximei Zhang, Dr. · Tianjin Medical University Cancer Institute and Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-20
Primary Completion
2024-10-19
Completion
2026-10-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05595590 on ClinicalTrials.gov